Showing results (421-430 of 554) with videos related to
Sort By:
Pageof 56
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 10, 2017
MSH2 Loss in Primary Prostate CancerLiana B Guedes, Emmanuel S Antonarakis, Michael T Schweizer, et al.Journal for Immunotherapy of Cancer|March 3, 2021
LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer typesLandon C Brown, Matthew D Tucker, Ramy Sedhom, et al.The Oncologist|March 5, 2026
Molecular Landscape of Prostate Cancers with Clival MetastasesPornlada Likasitwatanakul, Steven M Blinka, Jabra G Zarka, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkersEmmanuel S Antonarakis, Elisabeth I Heath, Janet R Walczak, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 24, 2015
Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate CancerSteven P Rowe, Katarzyna J Macura, Anthony Ciarallo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2021
A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate CancerPhillip L Palmbos, Stephanie Daignault-Newton, Scott A Tomlins, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 11, 2018
Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGYScott T Tagawa, Emmanuel S Antonarakis, Ada Gjyrezi, et al.Communications Biology|April 14, 2023
ALAN is a computational approach that interprets genomic findings in the context of tumor ecosystemsHannah E Bergom, Ashraf Shabaneh, Abderrahman Day, et al.NEJM Evidence|February 6, 2024
Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate CancerKarim Fizazi, Alice Bernard-Tessier, Guilhem Roubaud, et al.Cancers|May 25, 2024
Characterization of FOLH1 Expression in Renal Cell CarcinomaEric Ovruchesky, Elizabeth Pan, Melis Guer, et al.Pageof 56